Member Info for marik

Time for a tie and shirt.

Which one of you is stickystock?

Here are my thoughts, I'll contact the company directly, then take it from there.

Which one is stickystock?

Understood Bline, you're suggesting I be more pro-active and knock on other doors. You could be right, but let's see.

Anyone?

My choice would be:

Best Communication Award
Spire

Breakthrough of the Year Award
A close call, hopefully it's Synairgen but possibly Biontech.

Best Technology
Avacta (I'm not biased - honest)

Emerging Star
Artios

Mediscience Commentator of the Year Award
Natasha Loder/The Economist

Capital Market Transaction of the Year Award
Synairgen

Most Significant Contribution to the Mediscience Sector Award
Ugur Sahin and Özlem Türeci/BioNTech SE

Best Newcomer
Nanoform Finland plc

Chief Executive of the Year Award
Richard Marsden

Company of the Year Award
AZ/Biontech

My choice would be:

Best Communication Award
Spire

Breakthrough of the Year Award
A close call, hopefully it's Synairgen but possibly Biontech.

Best Technology
Avacta (I'm biased)

Emerging Star
Artios

Mediscience Commentator of the Year Award
Natasha Loder/The Economist

Capital Market Transaction of the Year Award
Synairgen

Most Significant Contribution to the Mediscience Sector Award
Ugur Sahin and Özlem Türeci/BioNTech SE

Best Newcomer
Nanoform Finland plc

Chief Executive of the Year Award
RM

Company of the Year Award
AZ/Biontech

Some great acquisitions going on. Sibanye-Stillwater making a very strong move. The words are "...miners across the globe try securing supplies of the metals used in batteries for electric cars and are key for the transition to a green economy".

Message the Omega board first, I noticed you haven't posted anything there for a long time.

Very odd.

It's very quite this evening. Where has everyone gone?

Pro-chemos would certainly be hitting at 5x or more the current accumulative dose. As long as the pK data from the trial goes as expected, I believe that this will be a very big positive.

(Griffith's definitely from the right part of the world and fantastic work through his career. Agree, there were many brave men on both sides)

Most experts providing market size will have taken the NICE and ICER into account, usually provides some base calculations. Thankfully there are experts out there who have done the hard work and provided the price of $250B on the market. Successful clinical results for preCISION would put the price in the multiples of the current chemotherapy market size.

@aj, do you know the cost of dox per patient at the moment, with a given number of cycles?

Rorkes, don't worry about it, I'll go with aj's reply.

Thanks aj, we can have physicians consultation chat another time ;0)
Rorkes I understand that you don't want to answer the question, don't worry if you don't know. I was interested.
Just to lighten the mood, did you know that Kenneth Griffith wrote the screenplay for Rorke's Drift?

Thanks aj, I agree with your points, but instead of provisionally taking this as purely med/pharm NICE and ICER equation, I'd like to find out what the health economics that Rorkes has researched.

As well as answering that, can you answer my initial question, what is the cap?

"I think the factoring was based on a simple more patients x more drug..." why would you think that?